| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Umang Swami | Q83863838 |
| P2093 | author name string | Sanjay Goel | |
| Imran Chaudhary | |||
| Mohammad H Ghalib | |||
| P2860 | cites work | Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability | Q24610709 |
| Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase | Q24657514 | ||
| In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B | Q28202233 | ||
| Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment | Q28255226 | ||
| The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth | Q28261808 | ||
| Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 | Q28277346 | ||
| Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data | Q28292051 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer | Q33330619 | ||
| Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer | Q33488625 | ||
| Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents | Q33630855 | ||
| Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial | Q33812323 | ||
| Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. | Q33941497 | ||
| Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q33990883 | ||
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | Q34022546 | ||
| Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. | Q34989416 | ||
| Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B | Q35183246 | ||
| Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? | Q37073084 | ||
| Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine | Q37777290 | ||
| Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer | Q37802209 | ||
| The Place for Eribulin in the Treatment of Metastatic Breast Cancer | Q37811984 | ||
| Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin | Q39787976 | ||
| Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. | Q40238368 | ||
| Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer | Q42653377 | ||
| Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization | Q42815194 | ||
| Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes | Q43068334 | ||
| Vinorelbine induces beta3-tubulin gene expression through an AP-1 Site. | Q43297205 | ||
| Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole | Q43861920 | ||
| Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. | Q45935600 | ||
| A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. | Q45976166 | ||
| Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. | Q45976200 | ||
| Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q46059531 | ||
| Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. | Q46353411 | ||
| Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin | Q48344692 | ||
| Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. | Q51533397 | ||
| Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer | Q56626150 | ||
| Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an | Q57578399 | ||
| Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer | Q57580011 | ||
| Halichondrins - antitumor polyether macrolides from a marine sponge | Q62773345 | ||
| Accelerated titration designs for phase I clinical trials in oncology | Q73598986 | ||
| Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts | Q73982426 | ||
| Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial | Q79847220 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 163-184 | |
| P577 | publication date | 2011-04-14 | |
| P1433 | published in | Critical Reviews in Oncology Hematology | Q15724423 |
| P1476 | title | Eribulin -- a review of preclinical and clinical studies | |
| P478 | volume | 81 |
| Q36443858 | A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium |
| Q38837821 | Anti-Microtubule Drugs |
| Q26777317 | Antimitotic drugs in the treatment of cancer |
| Q50045537 | Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY). |
| Q92854569 | Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure |
| Q90554778 | Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripheral Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Nerves |
| Q52603297 | Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan. |
| Q47628083 | Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer. |
| Q41592750 | Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines |
| Q90418687 | Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report |
| Q37654001 | Eribulin drug review |
| Q38686619 | Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer |
| Q26799328 | Eribulin in Cancer Treatment |
| Q39120142 | Eribulin in non-small cell lung cancer: challenges and potential strategies. |
| Q28074125 | Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival |
| Q38213846 | Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review |
| Q38267039 | Eribulin: a new-generation antimicrotubule agent in lung cancer therapy |
| Q38012442 | Eribulin: a novel cytotoxic chemotherapy agent |
| Q41988197 | Managing sarcoma: where have we come from and where are we going? |
| Q33815594 | Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy |
| Q64253409 | Neurymenolide A, a Novel Mitotic Spindle Poison from the New Caledonian Rhodophyta |
| Q36181279 | Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function |
| Q38220276 | Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. |
| Q90476597 | Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience |
| Q36273796 | Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products |
| Q40241837 | Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer |
| Q92669080 | Selectively high efficacy of eribulin against high-grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck |
| Q46592179 | Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer. |
Search more.